{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:19:50Z","timestamp":1791836390615,"version":"4.3.4"},"reference-count":105,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.hoc.2015.02.002","type":"journal-article","created":{"date-parts":[[2015,4,6]],"date-time":"2015-04-06T04:15:36Z","timestamp":1428293736000},"page":"541-559","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Thrombotic Microangiopathy"],"prefix":"10.1016","volume":"29","author":[{"given":"C. John","family":"Sperati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison R.","family":"Moliterno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.hoc.2015.02.002_bib1","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2015.02.002_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2369-14-3","article-title":"Thrombocytopenia is not mandatory to diagnose haemolytic and uremic syndrome","volume":"14","author":"Sall\u00e9e","year":"2013","journal-title":"BMC Nephrol"},{"issue":"6","key":"10.1016\/j.hoc.2015.02.002_bib3","doi-asserted-by":"crossref","first-page":"e1769","DOI":"10.1542\/peds.2013-2921","article-title":"Cryptic activity of atypical hemolytic uremic syndrome and eculizumab treatment","volume":"133","author":"Belingheri","year":"2014","journal-title":"Pediatrics"},{"key":"10.1016\/j.hoc.2015.02.002_bib4","first-page":"21","article-title":"Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease","volume":"24","author":"Moschcowitz","year":"1924","journal-title":"Proc N Y Pathol Soc"},{"issue":"38\u201339","key":"10.1016\/j.hoc.2015.02.002_bib5","first-page":"905","article-title":"Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia","volume":"85","author":"Gasser","year":"1955","journal-title":"Schweiz Med Wochenschr"},{"issue":"7835","key":"10.1016\/j.hoc.2015.02.002_bib6","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0140-6736(73)92645-7","article-title":"Letter: plasma-C3 in haemolytic-uraemic syndrome and thrombotic thrombocytopenic purpura","volume":"2","author":"Cameron","year":"1973","journal-title":"Lancet"},{"issue":"7883","key":"10.1016\/j.hoc.2015.02.002_bib7","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S0140-6736(74)90991-X","article-title":"Haemolytic-uraemic syndrome: evidence for intravascular C3 activation","volume":"304","author":"St\u00fchlinger","year":"1974","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.hoc.2015.02.002_bib8","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1523-1755.1998.00824.x","article-title":"Genetic studies into inherited and sporadic hemolytic uremic syndrome","volume":"53","author":"Warwicker","year":"1998","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.hoc.2015.02.002_bib9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1750-1172-6-60","article-title":"Atypical hemolytic uremic syndrome","volume":"6","author":"Loirat","year":"2011","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"10.1016\/j.hoc.2015.02.002_bib10","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00467-003-1385-9","article-title":"Clinico-pathological findings in diarrhoea-negative haemolytic uraemic syndrome","volume":"19","author":"Taylor","year":"2004","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"10.1016\/j.hoc.2015.02.002_bib11","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1055\/s-0034-1375701","article-title":"Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS)","volume":"40","author":"Sethi","year":"2014","journal-title":"Semin Thromb Hemost"},{"issue":"20","key":"10.1016\/j.hoc.2015.02.002_bib12","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1182\/blood-2010-07-271445","article-title":"How I treat patients with thrombotic thrombocytopenic purpura","volume":"116","author":"George","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2015.02.002_bib13","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrneph.2012.214","article-title":"Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies","volume":"8","author":"Zuber","year":"2012","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"10.1016\/j.hoc.2015.02.002_bib14","doi-asserted-by":"crossref","first-page":"e10208","DOI":"10.1371\/journal.pone.0010208","article-title":"Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience","volume":"5","author":"Coppo","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.hoc.2015.02.002_bib15","article-title":"Acute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity","author":"Zafrani","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"issue":"7","key":"10.1016\/j.hoc.2015.02.002_bib16","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/j.1538-7836.2005.01436.x","article-title":"The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency","volume":"3","author":"Terrell","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"issue":"10","key":"10.1016\/j.hoc.2015.02.002_bib17","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/pbc.24612","article-title":"Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features","volume":"60","author":"Reese","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2015.02.002_bib18","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1053\/j.ajkd.2004.02.010","article-title":"Non-enteropathic hemolytic uremic syndrome: causes and short-term course","volume":"43","author":"Constantinescu","year":"2004","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.hoc.2015.02.002_bib19","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.hoc.2015.02.002_bib20","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.hoc.2015.02.002_bib21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1469-1809.2009.00554.x","article-title":"Epidemiological approach to identifying genetic predispositions for atypical hemolytic uremic syndrome","volume":"74","author":"Sullivan","year":"2010","journal-title":"Ann Hum Genet"},{"key":"10.1016\/j.hoc.2015.02.002_bib22","series-title":"Characteristics of 406 adult and pediatric patients in the global aHUS registry","author":"Licht","year":"2014"},{"issue":"5","key":"10.1016\/j.hoc.2015.02.002_bib23","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1681\/ASN.2009070706","article-title":"Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations","volume":"21","author":"Fakhouri","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.hoc.2015.02.002_bib24","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1182\/blood.V98.9.2730","article-title":"Changes in health and disease of the metalloprotease that cleaves von Willebrand factor","volume":"98","author":"Mannucci","year":"2001","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2015.02.002_bib25","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1111\/j.1600-6143.2008.02297.x","article-title":"Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation","volume":"8","author":"Le Quintrec","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.hoc.2015.02.002_bib26","series-title":"Fundamental immunology","article-title":"Complement","author":"Morgan","year":"2012"},{"issue":"6","key":"10.1016\/j.hoc.2015.02.002_bib27","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.ajhg.2011.05.011","article-title":"Disease-causing mutations in genes of the complement system","volume":"88","author":"Degn","year":"2011","journal-title":"Am J Hum Genet"},{"issue":"12","key":"10.1016\/j.hoc.2015.02.002_bib28","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1002\/stem.1801","article-title":"Brief report: complement c5a promotes human embryonic stem cell pluripotency in the absence of FGF2","volume":"32","author":"Hawksworth","year":"2014","journal-title":"Stem Cells"},{"issue":"6","key":"10.1016\/j.hoc.2015.02.002_bib29","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nm1419","article-title":"Generation of C5a in the absence of C3: a new complement activation pathway","volume":"12","author":"Huber-Lang","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2015.02.002_bib30","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2014050429","article-title":"Complement Factor C4d Is a Common Denominator in Thrombotic Microangiopathy","author":"Chua","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.hoc.2015.02.002_bib31","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1749-6632.1983.tb18116.x","article-title":"Initiation of the alternative complement pathway due to spontaneous hydrolysis of the thioester of C3","volume":"421","author":"Pangburn","year":"1983","journal-title":"Ann N Y Acad Sci"},{"issue":"11","key":"10.1016\/j.hoc.2015.02.002_bib32","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.imbio.2012.07.008","article-title":"The tick-over theory revisited: is C3 a contact-activated protein?","volume":"217","author":"Nilsson","year":"2012","journal-title":"Immunobiology"},{"key":"10.1016\/j.hoc.2015.02.002_bib33","doi-asserted-by":"crossref","DOI":"10.2215\/CJN.06230614","article-title":"Molecules great and small: the complement system","author":"Mathern","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"issue":"15","key":"10.1016\/j.hoc.2015.02.002_bib34","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1021\/bi00518a034","article-title":"Nucleophilic modification of human complement protein C3: correlation of conformational changes with acquisition of C3b-like functional properties","volume":"20","author":"Isenman","year":"1981","journal-title":"Biochemistry"},{"issue":"3","key":"10.1016\/j.hoc.2015.02.002_bib35","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.molimm.2013.06.001","article-title":"Complement factor H related proteins (CFHRs)","volume":"56","author":"Skerka","year":"2013","journal-title":"Mol Immunol"},{"issue":"7","key":"10.1016\/j.hoc.2015.02.002_bib36","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1136\/jmg.2008.064766","article-title":"The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome","volume":"46","author":"Dragon-Durey","year":"2009","journal-title":"J\u00a0Med Genet"},{"issue":"2","key":"10.1016\/j.hoc.2015.02.002_bib37","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood-2009-05-221549","article-title":"Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome","volume":"115","author":"Moore","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2015.02.002_bib38","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1182\/blood-2006-03-012567","article-title":"Thrombin-activatable procarboxypeptidase B regulates activated complement C5a in\u00a0vivo","volume":"109","author":"Nishimura","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2015.02.002_bib39","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1538-7836.2010.03787.x","article-title":"What has been learnt from the thrombin-activatable fibrinolysis inhibitor-deficient mouse?","volume":"8","author":"Morser","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"10.1016\/j.hoc.2015.02.002_bib40","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00281-011-0282-8","article-title":"Thrombomodulin and its role in inflammation","volume":"34","author":"Conway","year":"2012","journal-title":"Semin Immunopathol"},{"issue":"22","key":"10.1016\/j.hoc.2015.02.002_bib41","doi-asserted-by":"crossref","first-page":"18831","DOI":"10.1074\/jbc.M111.323287","article-title":"Plasminogen is a complement inhibitor","volume":"287","author":"Barthel","year":"2012","journal-title":"J\u00a0Biol Chem"},{"issue":"6","key":"10.1016\/j.hoc.2015.02.002_bib42","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ejim.2012.12.016","article-title":"The endothelial glycocalyx as a potential modifier of the hemolytic uremic syndrome","volume":"24","author":"Boels","year":"2013","journal-title":"Eur J Intern Med"},{"issue":"3","key":"10.1016\/j.hoc.2015.02.002_bib43","first-page":"348","article-title":"Complement C3 gene expression and regulation in human glomerular epithelial cells","volume":"79","author":"Sacks","year":"1993","journal-title":"Immunology"},{"issue":"7","key":"10.1016\/j.hoc.2015.02.002_bib44","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.20132413","article-title":"Neutrophils recruited by chemoattractants in\u00a0vivo induce microvascular plasma protein leakage through secretion of TNF","volume":"211","author":"Finsterbusch","year":"2014","journal-title":"J\u00a0Exp Med"},{"issue":"7","key":"10.1016\/j.hoc.2015.02.002_bib45","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.4049\/jimmunol.177.7.4794","article-title":"A\u00a0novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways","volume":"177","author":"Ritis","year":"2006","journal-title":"J\u00a0Immunol"},{"issue":"11","key":"10.1016\/j.hoc.2015.02.002_bib46","doi-asserted-by":"crossref","first-page":"7368","DOI":"10.4049\/jimmunol.180.11.7368","article-title":"C5a and TNF- up-regulate the expression of tissue factor in intra-alveolar neutrophils of patients with the acute respiratory distress syndrome","volume":"180","author":"Kambas","year":"2008","journal-title":"J\u00a0Immunol"},{"issue":"2","key":"10.1016\/j.hoc.2015.02.002_bib47","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood-2013-03-489245","article-title":"Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome","volume":"122","author":"Frimat","year":"2013","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.hoc.2015.02.002_bib48","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1182\/blood-2009-03-205096","article-title":"Platelet-associated complement factor H in healthy persons and patients with atypical HUS","volume":"114","author":"Licht","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2015.02.002_bib49","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1182\/blood-2007-08-106153","article-title":"Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation","volume":"111","author":"St\u00e5hl","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2015.02.002_bib50","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2013-04-495853","article-title":"The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status","volume":"123","author":"Rayes","year":"2014","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2015.02.002_bib51","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/jth.12225","article-title":"The secretion of von Willebrand factor from endothelial cells; an increasingly complicated story","volume":"11","author":"Nightingale","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.hoc.2015.02.002_bib52","unstructured":"Soliris [package insert]. Cheshire, CT: Alexion Pharmaceuticals, Inc; 2014."},{"issue":"23","key":"10.1016\/j.hoc.2015.02.002_bib53","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.hoc.2015.02.002_bib54","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.semnephrol.2013.08.003","article-title":"Atypical hemolytic uremic syndrome","volume":"33","author":"Kavanagh","year":"2013","journal-title":"Semin Nephrol"},{"issue":"3","key":"10.1016\/j.hoc.2015.02.002_bib55","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2215\/CJN.05750611","article-title":"Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon?","volume":"7","author":"Kavanagh","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3 Pt 2","key":"10.1016\/j.hoc.2015.02.002_bib56","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1016\/j.lpm.2011.11.013","article-title":"Management of hemolytic uremic syndrome","volume":"41","author":"Loirat","year":"2012","journal-title":"Presse Med"},{"issue":"7","key":"10.1016\/j.hoc.2015.02.002_bib57","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/jhg.2012.57","article-title":"Atypical hemolytic uremic syndrome and genetic aberrations in the complement factor H-related 5 gene","volume":"57","author":"Westra","year":"2012","journal-title":"J\u00a0Hum Genet"},{"issue":"5","key":"10.1016\/j.hoc.2015.02.002_bib58","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/ng.2590","article-title":"Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome","volume":"45","author":"Lemaire","year":"2013","journal-title":"Nat Genet"},{"issue":"11\u201312","key":"10.1016\/j.hoc.2015.02.002_bib59","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1016\/j.molimm.2009.04.012","article-title":"A\u00a0novel mutation in the complement regulator clusterin in recurrent hemolytic uremic syndrome","volume":"46","author":"St\u00e5hl","year":"2009","journal-title":"Mol Immunol"},{"issue":"1","key":"10.1016\/j.hoc.2015.02.002_bib60","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1681\/ASN.2013050453","article-title":"Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome","volume":"25","author":"Bu","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.hoc.2015.02.002_bib61","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2011-03-339903","article-title":"A\u00a0novel hybrid CFH\/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome","volume":"119","author":"Francis","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2015.02.002_bib62","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa0810739","article-title":"Thrombomodulin mutations in atypical hemolytic-uremic syndrome","volume":"361","author":"Delvaeye","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2015.02.002_bib63","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1055\/s-0034-1376153","article-title":"Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches","volume":"40","author":"Riedl","year":"2014","journal-title":"Semin Thromb Hemost"},{"issue":"4","key":"10.1016\/j.hoc.2015.02.002_bib64","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1055\/s-0034-1375296","article-title":"Genetics of atypical hemolytic uremic syndrome (aHUS)","volume":"40","author":"Rodr\u00edguez de C\u00f3rdoba","year":"2014","journal-title":"Semin Thromb Hemost"},{"issue":"6","key":"10.1016\/j.hoc.2015.02.002_bib65","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood-2014-06-579953","article-title":"Loss of DGK\u03b5 induces endothelial cell activation and death independently of complement activation","volume":"125","author":"Bruneau","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2015.02.002_bib66","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1681\/ASN.2013080886","article-title":"Phenotypic expansion of DGKE-associated diseases","volume":"25","author":"Westland","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.hoc.2015.02.002_bib67","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.ajkd.2013.08.031","article-title":"Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency","volume":"63","author":"Cornec-Le Gall","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"10.1016\/j.hoc.2015.02.002_bib68","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2015.02.002_bib69","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00428-013-1386-4","article-title":"Comprehensive analysis of glomerular mRNA expression of pro- and antithrombotic genes in atypical haemolytic-uremic syndrome (aHUS)","volume":"462","author":"Modde","year":"2013","journal-title":"Virchows Arch"},{"issue":"1","key":"10.1016\/j.hoc.2015.02.002_bib70","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa011033","article-title":"Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome","volume":"346","author":"Chandler","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2015.02.002_bib71","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1046\/j.1523-1755.1998.00103.x","article-title":"Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome","volume":"54","author":"Van Geet","year":"1998","journal-title":"Kidney Int"},{"issue":"10","key":"10.1016\/j.hoc.2015.02.002_bib72","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00467-002-0906-2","article-title":"Fibrinolysis in the hemolytic uremic syndrome","volume":"17","author":"Proesmans","year":"2002","journal-title":"Pediatr Nephrol"},{"issue":"12","key":"10.1016\/j.hoc.2015.02.002_bib73","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1161\/CIRCULATIONAHA.113.006727","article-title":"Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy","volume":"129","author":"Tersteeg","year":"2014","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.hoc.2015.02.002_bib74","doi-asserted-by":"crossref","first-page":"e59372","DOI":"10.1371\/journal.pone.0059372","article-title":"Assembly and activation of alternative complement components on endothelial cell-anchored ultra-large von Willebrand factor links complement and hemostasis-thrombosis","volume":"8","author":"Turner","year":"2013","journal-title":"PLoS One"},{"issue":"22","key":"10.1016\/j.hoc.2015.02.002_bib75","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJM199811263392202","article-title":"von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome","volume":"339","author":"Furlan","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.hoc.2015.02.002_bib76","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2001-12-0166","article-title":"von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome","volume":"100","author":"Remuzzi","year":"2002","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2015.02.002_bib77","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1182\/blood-2013-03-492421","article-title":"Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome","volume":"122","author":"Feng","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2015.02.002_bib78","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of complement activation in aHUS and how to monitor eculizumab therapy","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2015.02.002_bib79","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/jth.12615","article-title":"Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome","volume":"12","author":"Cugno","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"issue":"24","key":"10.1016\/j.hoc.2015.02.002_bib80","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2013-12-547067","article-title":"Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP","volume":"123","author":"Cataland","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2015.02.002_bib81","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.molimm.2004.01.003","article-title":"Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in factor H","volume":"41","author":"S\u00e1nchez-Corral","year":"2004","journal-title":"Mol Immunol"},{"issue":"7","key":"10.1016\/j.hoc.2015.02.002_bib82","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic variants in C5 and poor response to eculizumab","volume":"370","author":"Nishimura","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2015.02.002_bib83","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.bbmt.2013.12.565","article-title":"Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"20","author":"Jodele","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.hoc.2015.02.002_bib84","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1681\/ASN.2012090884","article-title":"Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype","volume":"24","author":"Bresin","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"33","key":"10.1016\/j.hoc.2015.02.002_bib85","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2010030315","article-title":"Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome","volume":"21","author":"Dragon-Durey","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.hoc.2015.02.002_bib86","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1053\/j.ajkd.2009.12.026","article-title":"Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies","volume":"55","author":"Boyer","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.hoc.2015.02.002_bib87","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00467-013-2654-x","article-title":"Successful treatment of DEAP-HUS with eculizumab","volume":"29","author":"Noone","year":"2014","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"10.1016\/j.hoc.2015.02.002_bib88","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1053\/j.ajkd.2014.01.434","article-title":"Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases","volume":"64","author":"Ardissino","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.hoc.2015.02.002_bib89","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1111\/j.1600-6143.2012.04252.x","article-title":"Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation","volume":"12","author":"Zuber","year":"2012","journal-title":"Am J Transplant"},{"issue":"11","key":"10.1016\/j.hoc.2015.02.002_bib90","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1097\/TP.0000000000000200","article-title":"Atypical hemolytic uremic syndrome recurrence after kidney transplantation","volume":"98","author":"Matar","year":"2014","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.hoc.2015.02.002_bib91","doi-asserted-by":"crossref","first-page":"e928","DOI":"10.1542\/peds.2012-1466","article-title":"A\u00a0novel strategy for hemolytic uremic syndrome: successful treatment with thrombomodulin \u03b1","volume":"131","author":"Honda","year":"2013","journal-title":"Pediatrics"},{"issue":"9","key":"10.1016\/j.hoc.2015.02.002_bib92","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2215\/CJN.01640214","article-title":"Complement mutations in diacylglycerol kinase-\u03b5-associated atypical hemolytic uremic syndrome","volume":"9","author":"S\u00e1nchez Chinchilla","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.hoc.2015.02.002_bib93","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0022-3476(73)80490-1","article-title":"Heparin therapy in the hemolytic-uremic syndrome","volume":"83","author":"Vitacco","year":"1973","journal-title":"J\u00a0Pediatr"},{"issue":"1","key":"10.1016\/j.hoc.2015.02.002_bib94","first-page":"15","article-title":"Treatment of childhood hemolytic-uremic syndrome with urokinase. Cooperative controlled trial","volume":"41","author":"Loirat","year":"1984","journal-title":"Arch Fr Pediatr"},{"issue":"1","key":"10.1016\/j.hoc.2015.02.002_bib95","article-title":"Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura","author":"Michael","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.hoc.2015.02.002_bib96","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/nm1121","article-title":"Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation","volume":"10","author":"Girardi","year":"2004","journal-title":"Nat Med"},{"issue":"1 Pt 2","key":"10.1016\/j.hoc.2015.02.002_bib97","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.33.1.232","article-title":"Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats","volume":"33","author":"Rocha","year":"1999","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.hoc.2015.02.002_bib98","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/10641963.2010.503303","article-title":"Clinical features of malignant hypertension with thrombotic microangiopathy","volume":"33","author":"Akimoto","year":"2011","journal-title":"Clin Exp Hypertens"},{"issue":"10 Pt 2","key":"10.1016\/j.hoc.2015.02.002_bib99","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1016\/j.lpm.2014.02.031","article-title":"Kidney involvement in systemic sclerosis","volume":"43","author":"Steen","year":"2014","journal-title":"Presse Med"},{"issue":"4","key":"10.1016\/j.hoc.2015.02.002_bib100","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.4049\/jimmunol.111.4.1061","article-title":"Effect of cortisone therapy on serum complement components","volume":"111","author":"Atkinson","year":"1973","journal-title":"J\u00a0Immunol"},{"issue":"4","key":"10.1016\/j.hoc.2015.02.002_bib101","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1172\/JCI109365","article-title":"Corticosteroids inhibit complement-induced granulocyte aggregation. A possible mechanism for their efficacy in shock states","volume":"63","author":"Hammerschmidt","year":"1979","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.hoc.2015.02.002_bib102","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-230X-5-31","article-title":"Complement activation capacity in plasma before and during high-dose prednisolone treatment and tapering in exacerbations of Crohn\u2019s disease and ulcerative colitis","volume":"5","author":"Zimmermann-Nielsen","year":"2005","journal-title":"BMC Gastroenterol"},{"issue":"5","key":"10.1016\/j.hoc.2015.02.002_bib103","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1681\/ASN.2005010086","article-title":"Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement","volume":"16","author":"Noris","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.hoc.2015.02.002_bib104","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/ki.2011.291","article-title":"Complement factor H variants I890 and L1007 while commonly associated with atypical hemolytic uremic syndrome are polymorphisms with no functional significance","volume":"81","author":"Tortajada","year":"2012","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.hoc.2015.02.002_bib105","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1681\/ASN.2013070796","article-title":"Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign?","volume":"25","author":"Marinozzi","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858815000222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858815000222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:01:40Z","timestamp":1760184100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858815000222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":105,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0889858815000222"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2015.02.002","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombotic Microangiopathy","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2015.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}